BDTX Black Diamond Therapeutics
- 4.980
- -0.340-6.39%
- 5.100
- +0.120+2.41%
Black Diamond Therapeutics News
Black Diamond Therapeutic Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target
HC Wainwright & Co. : Maintaining the Black Diamond Therapeutic (BDTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $11.00.
Black Diamond Therapeutic Analyst Ratings
HC Wainwright & Co. Maintains Buy on Black Diamond Therapeutic, Lowers Price Target to $11
Buy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical Trials
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
Wedbush: Maintaining the Black Diamond Therapeutic (BDTX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $10.00 to $16.00.
Black Diamond Therapeutic Analyst Ratings
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating
Black Diamond Therapeutic Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
Black Diamond Therapeutic Analyst Ratings
Black Diamond Therapeutics (BDTX) Receives a Buy From TD Cowen
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA)
Analysts' Top Healthcare Picks: Black Diamond Therapeutics (BDTX), Amylyx Pharmaceuticals Inc (AMLX)
Black Diamond Therapeutic Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics (BDTX) Receives a Buy From Piper Sandler
Wedbush Reiterates Outperform on Black Diamond Therapeutic, Maintains $10 Price Target
Analysis
Price Target
No Data
